SUBSCRIBE
SUBSCRIBE

GLP-1

Job Trends
Potential Mechanisms for Future Anti-Obesity Drugs Identified, University of Pennsylvania Study
March 4, 2011
 · 
3 min read
Biotech Bay
How Weight-Loss Surgery Reverses Type 2 Diabetes: University of California, Davis (UCD) New Study Offers Explanation
March 25, 2010
 · 
6 min read
Obesity And Type 2 Diabetes Market Closely Linked But Vastly Different In Outlook
March 10, 2010
 · 
3 min read
Drug Development
Novo Nordisk A/S New Diabetes Drug Liraglutide Works Well In Trial; Could Be Approved For U.S. Market By Next Year, Baylor College of Medicine Researcher Says
September 25, 2008
 · 
3 min read
WuXi PharmaTech Co., Ltd. and Covance Inc. Will Partner in JV
June 25, 2008
 · 
1 min read
Business
The Week in Review: Anesiva, Inc. Forms JV with Fosun Pharma
October 15, 2007
 · 
1 min read
Business
WuXi PharmaTech Co., Ltd. Begins Building GLP Center in Suzhou
October 9, 2007
 · 
1 min read
Business
ConjuChem
October 19, 2005
 · 
8 min read
Load More
PRESS RELEASES
Press Releases
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
November 12, 2025
 · 
6 min read
Press Releases
Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide
November 10, 2025
 · 
4 min read
Press Releases
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 6, 2025
 · 
10 min read
Press Releases
OrsoBio to Present Clinical and Preclinical Data on Mitochondrial Protonophore Portfolio for Obesity at ObesityWeek® 2025
November 5, 2025
 · 
7 min read
Press Releases
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
November 5, 2025
 · 
7 min read
Press Releases
Veloxity Labs Acquires SCIEX Accurate Mass Spectrometer, the ZenoTOF 8600 System, to Accelerate Peptide and Complex Bioanalysis
November 5, 2025
 · 
4 min read
Press Releases
Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
November 5, 2025
 · 
7 min read
Press Releases
Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users
November 5, 2025
 · 
5 min read
Press Releases
Aion Medicines Presents Data at ObesityWeek Demonstrating Ultra-long-acting Pharmacokinetics and Pharmacodynamic Effects of AM-710, a Potential Best-in-class GLP-1 Receptor Agonist and the Longest Acting Incretin Identified to Date
November 4, 2025
 · 
3 min read
Press Releases
Immunis Publishes Research Showing Body Fat Loss and Reversal of Liver Steatosis and Fibrosis, While Increasing Lean Muscle Mass, in Aged Models
November 2, 2025
 · 
3 min read
Press Releases
Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
October 29, 2025
 · 
10 min read
Press Releases
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
October 28, 2025
 · 
5 min read
Press Releases
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
October 28, 2025
 · 
6 min read
Press Releases
Innovent’s Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
October 27, 2025
 · 
9 min read
Press Releases
Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity
October 21, 2025
 · 
7 min read
Press Releases
FDA approves Novo Nordisk’s oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
October 20, 2025
 · 
12 min read
Press Releases
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
October 19, 2025
 · 
4 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
October 16, 2025
 · 
9 min read
Press Releases
Alpha Genesis Expands GLP Capacity Following Multi-Million-Dollar Investment to Accelerate IND-Enabling Nonhuman Primate Studies
October 15, 2025
 · 
3 min read
Press Releases
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
October 13, 2025
 · 
6 min read
Load More